268 related articles for article (PubMed ID: 8028034)
1. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.
Meyskens FL; Emerson SS; Pelot D; Meshkinpour H; Shassetz LR; Einspahr J; Alberts DS; Gerner EW
J Natl Cancer Inst; 1994 Aug; 86(15):1122-30. PubMed ID: 8028034
[TBL] [Abstract][Full Text] [Related]
2. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
[TBL] [Abstract][Full Text] [Related]
3. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
Thompson PA; Wertheim BC; Zell JA; Chen WP; McLaren CE; LaFleur BJ; Meyskens FL; Gerner EW
Gastroenterology; 2010 Sep; 139(3):797-805, 805.e1. PubMed ID: 20538001
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia.
Mitchell MF; Tortolero-Luna G; Lee JJ; Hittelman WN; Lotan R; Wharton JT; Hong WK; Nishioka K
Clin Cancer Res; 1998 Feb; 4(2):303-10. PubMed ID: 9516915
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
[TBL] [Abstract][Full Text] [Related]
6. Polyamines as biomarkers of cervical intraepithelial neoplasia.
Nishioka K; Melgarejo AB; Lyon RR; Mitchell MF
J Cell Biochem Suppl; 1995; 23():87-95. PubMed ID: 8747382
[TBL] [Abstract][Full Text] [Related]
7. Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial.
Pendyala L; Creaven PJ; Porter CW
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):235-41. PubMed ID: 8318876
[TBL] [Abstract][Full Text] [Related]
8. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
Love RR; Carbone PP; Verma AK; Gilmore D; Carey P; Tutsch KD; Pomplun M; Wilding G
J Natl Cancer Inst; 1993 May; 85(9):732-7. PubMed ID: 8478959
[TBL] [Abstract][Full Text] [Related]
10. Behavioral and neurochemical effects of acute putrescine depletion by difluoromethylornithine in rats.
Gupta N; Zhang H; Liu P
Neuroscience; 2009 Jul; 161(3):691-706. PubMed ID: 19348875
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine.
Gerner EW; Garewal HS; Emerson SS; Sampliner RE
Cancer Epidemiol Biomarkers Prev; 1994 Jun; 3(4):325-30. PubMed ID: 8061581
[TBL] [Abstract][Full Text] [Related]
12. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
13. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine.
Boyle JO; Meyskens FL; Garewal HS; Gerner EW
Cancer Epidemiol Biomarkers Prev; 1992; 1(2):131-5. PubMed ID: 1306095
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of proximal small intestinal mucosal growth by luminal polyamines.
Wang JY; McCormack SA; Viar MJ; Johnson LR
Am J Physiol; 1991 Sep; 261(3 Pt 1):G504-11. PubMed ID: 1716059
[TBL] [Abstract][Full Text] [Related]
15. Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer.
Meyskens FL; Gerner EW
J Cell Biochem Suppl; 1995; 22():126-31. PubMed ID: 8538189
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of polyamine synthesis induces p53 gene expression but not apoptosis.
Li L; Li J; Rao JN; Li M; Bass BL; Wang JY
Am J Physiol; 1999 Apr; 276(4):C946-54. PubMed ID: 10199827
[TBL] [Abstract][Full Text] [Related]
17. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
18. Urinary polyamine levels in cancer patients treated with D,L-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis.
Horn Y; Spigel L; Marton LJ
J Surg Oncol; 1989 Jul; 41(3):177-82. PubMed ID: 2501593
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ornithine decarboxylase activity decreases polyamines and suppresses DNA synthesis in human colonic lamina propria lymphocytes.
Elitsur Y; Strom J; Luk GD
Immunopharmacology; 1993; 25(3):253-60. PubMed ID: 8354641
[TBL] [Abstract][Full Text] [Related]
20. Colonic polyamine content and ornithine decarboxylase activity as markers for adenomas.
McGarrity TJ; Peiffer LP; Bartholomew MJ; Pegg AE
Cancer; 1990 Oct; 66(7):1539-43. PubMed ID: 2208006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
